Provided by Tiger Trade Technology Pte. Ltd.

ASCLETIS-B

9.940
+0.4004.19%
Volume:1.70M
Turnover:17.33M
Market Cap:10.46B
PE:-26.86
High:10.600
Open:9.800
Low:9.500
Close:9.540
52wk High:19.860
52wk Low:7.950
Shares:1.05B
HK Float Shares:1.05B
Volume Ratio:2.48
T/O Rate:0.16%
Dividend:- -
Dividend Rate:- -
EPS(LYR):-0.370
ROE:-28.59%
ROA:-20.12%
PB:3.95
PE(LYR):-26.86
PS:9468.77

Loading ...

ASCLETIS-B Nears Previous Peak, But Why Are Investors Staying on the Sidelines?

Stock News
·
Apr 18

ASCLETIS-B Shares Surge Nearly 5% in Afternoon Trading, Approaching All-Time High as GLP-1 and Amylin Combo Enters Clinical Trials

Stock News
·
Apr 17

Analysts Are Optimistic We'll See A Profit From Ascletis Pharma Inc. (HKG:1672)

Simply Wall St.
·
Apr 09

ASCLETIS-B Maintains Stable Share Base in March; No New Issuance, Public Float Fully Compliant

Bulletin Express
·
Apr 08

ASCLETIS-B Advances Clinical Development of Fixed-Dose Combination ASC30_39 for Obesity Treatment

Stock News
·
Apr 07

BRIEF-Ascletis Announces Fixed-Dose Combination of ASC30, Once-Daily Oral Small Molecule GLP-1R Agonist, and ASC39, Once-Daily Oral Small Molecule Amylin-Selective Amylin Receptor Agonist, for Clinical Development

Reuters
·
Apr 07

Ascletis Accelerates Obesity Pipeline with First-in-Class Oral GLP-1/Amylin Fixed-Dose Combo; IND Targeted for Q3 2026

Bulletin Express
·
Apr 07

Ascletis Pharma Inc - Expects Ind Submission to FDA for Asc30_39 Fdc in Q3 2026

THOMSON REUTERS
·
Apr 07

Ascletis targets Q3 2026 FDA IND filing for oral obesity combo ASC30_39 tablet

Reuters
·
Apr 07

Ascletis Pharma's Loss Widens 20% in 2025; Shares Rise 5%

MT Newswires Live
·
Apr 01

BRIEF-Ascletis Pharma FY Loss Attributable Rmb359.9 Million

Reuters
·
Apr 01

ASCLETIS-B Reports Annual Loss Attributable to Shareholders of 360 Million Yuan, Widening 19.6% Year-on-Year

Stock News
·
Mar 31

Ascletis Pharma Inc - FY Loss Attributable RMB359.9 Mln

THOMSON REUTERS
·
Mar 31

HK Pharma Stocks Gained. CSPC Pharma Up 13%; Lepu Bio Up 7%; Hengrui Pharma And Junshi Bio Up 6%; HBM, Beigene, Sihuan Pharm Up 5%

Tiger Newspress
·
Mar 27

HK Pharma Stocks Gained. XuanzhuBio Up 9%; Xtalpi, Lepu Bio And Ascletis Up 6%; Akeso Up 5%; Skb Bio Up 4%.

Tiger Newspress
·
Mar 26

HK Pharma Stocks Gained. Wuxi XDC Up 8%; Wuxi AppTec Up 7%; Transthera And HBM Up 5%; Keymed Bio And Innocare Up 4%; Wuxi Bio And Remegen Up 3%

Tiger Newspress
·
Mar 24

BRIEF-Ascletis Pharma Expects To Submit IND Application To U.S. FDA For ASC39 In Q3 2026

Reuters
·
Mar 17

Ascletis targets Q3 2026 FDA IND filing for ASC39 oral obesity tablets

Reuters
·
Mar 17

ASCLETIS-B Selects Oral Amylin Receptor Agonist ASC39 as Clinical Candidate, Demonstrating Eloralintide-Like Selectivity and Efficacy in Preclinical Models

Stock News
·
Mar 17

Ascletis Pharma Inc - Expects to Submit Ind Application to U.S. FDA for Asc39 Oral Tablets in Q3 2026

THOMSON REUTERS
·
Mar 17